OR WAIT null SECS
February 28, 2022
Johnson & Johnson has confirmed advancement of the nationwide opioid settlement agreement.
Pfizer and BioNTech receive positive opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in the EU.
February 25, 2022
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure.
February 24, 2022
FDA licenses Certara’s Immunogenicity Simulator to research and evaluate immunogenicity in protein-based therapeutics.
TFF Pharmaceuticals announces findings that inhaled niclosamide significantly inhibits viral replication of the Omicron variant of SARS-CoV-2.
Medicago and GSK have announced that Health Canada has approved COVIFENZ, an adjuvanted plant-based COVID-19 vaccine.
USP is developing mRNA quality guidelines to help companies and regulators bring innovative medicines to market faster.
Scottish Enterprise has awarded £20 million (US$27 million) to Valneva Scotland to advance vaccine development.
February 23, 2022
Sanofi and GSK announce they are seeking regulatory authorization for COVID-19 vaccine.
MHRA has opened a consultation on the proposed changes to clinical trial legislation in the UK.